Do analysts rate AVNS or SMTI?

Sanara MedTech has a consensus price target of $35.00, suggesting a potential downside of 0.40%. Given Sanara MedTech's stronger consensus rating and higher possible upside, analysts clearly believe Sanara MedTech is more favorable than Avanos Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avanos Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Sanara MedTech 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80

Which has preferable earnings & valuation, CERS or SMTI?

Cerus has higher revenue and earnings than Sanara MedTech. Cerus is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cerus $206.13M 2.21 -$15.63M -$0.03 N/A Sanara MedTech $103.12M 3.13 -$37.56M -$3.59 N/A

Is CERS or SMTI more profitable?

Cerus has a net margin of -3.06% compared to Sanara MedTech's net margin of -29.15%. Sanara MedTech's return on equity of 29.72% beat Cerus' return on equity. Company Net Margins Return on Equity Return on Assets Cerus -3.06% -10.19% -3.14% Sanara MedTech -29.15% 29.72% 2.84%

Which has better earnings and valuation, SMTI or EMBC?

Embecta has higher revenue and earnings than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sanara MedTech $103.12M 3.13 -$37.56M -$3.59 N/A Embecta $1.08B 0.33 $95.40M $1.48 4.19

Is SMTI or EMBC more profitable?

Embecta has a net margin of 8.59% compared to Sanara MedTech's net margin of -29.15%. Sanara MedTech's return on equity of 29.72% beat Embecta's return on equity. Company Net Margins Return on Equity Return on Assets Sanara MedTech -29.15% 29.72% 2.84% Embecta 8.59% -19.25% 10.82%

Sanara MedTech (SMTI) Competitors

$35.13 -0.02 (-0.06%)

As of 10/13/2026 04:00 PM Eastern

Compare

SMTI vs. AVNS, QDEL, CERS, EMBC, and OSUR

Should you buy Sanara MedTech stock or one of its competitors? Sanara MedTech's main competitors and comparable companies include Avanos Medical (AVNS), QuidelOrtho (QDEL), Cerus (CERS), Embecta (EMBC), and OraSure Technologies (OSUR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare supplies" industry.

How does Sanara MedTech compare to Avanos Medical?

Avanos Medical (NYSE:AVNS) and Sanara MedTech (NASDAQ:SMTI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends, media sentiment and analyst recommendations.

Sanara MedTech has a consensus price target of $35.00, suggesting a potential downside of 0.40%. Given Sanara MedTech's stronger consensus rating and higher possible upside, analysts clearly believe Sanara MedTech is more favorable than Avanos Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avanos Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Sanara MedTech	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Avanos Medical has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market.

Avanos Medical has a net margin of -10.39% compared to Sanara MedTech's net margin of -29.15%. Sanara MedTech's return on equity of 29.72% beat Avanos Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avanos Medical	-10.39%	5.39%	3.97%
Sanara MedTech	-29.15%	29.72%	2.84%

In the previous week, Sanara MedTech had 1 more articles in the media than Avanos Medical. MarketBeat recorded 1 mentions for Sanara MedTech and 0 mentions for Avanos Medical. Sanara MedTech's average media sentiment score of 0.60 beat Avanos Medical's score of 0.00 indicating that Sanara MedTech is being referred to more favorably in the news media.

Company	Overall Sentiment
Avanos Medical	Neutral
Sanara MedTech	Positive

Sanara MedTech has lower revenue, but higher earnings than Avanos Medical. Avanos Medical is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avanos Medical	$715.90M	1.64	-$72.90M	-$1.61	N/A
Sanara MedTech	$103.12M	3.13	-$37.56M	-$3.59	N/A

95.2% of Avanos Medical shares are held by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are held by institutional investors. 2.3% of Avanos Medical shares are held by insiders. Comparatively, 42.0% of Sanara MedTech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Sanara MedTech beats Avanos Medical on 9 of the 15 factors compared between the two stocks.

How does Sanara MedTech compare to QuidelOrtho?

QuidelOrtho (NASDAQ:QDEL) and Sanara MedTech (NASDAQ:SMTI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

Sanara MedTech has a net margin of -29.15% compared to QuidelOrtho's net margin of -39.20%. Sanara MedTech's return on equity of 29.72% beat QuidelOrtho's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
QuidelOrtho	-39.20%	4.88%	1.63%
Sanara MedTech	-29.15%	29.72%	2.84%

99.0% of QuidelOrtho shares are held by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are held by institutional investors. 1.1% of QuidelOrtho shares are held by insiders. Comparatively, 42.0% of Sanara MedTech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, QuidelOrtho had 6 more articles in the media than Sanara MedTech. MarketBeat recorded 7 mentions for QuidelOrtho and 1 mentions for Sanara MedTech. Sanara MedTech's average media sentiment score of 0.60 beat QuidelOrtho's score of 0.46 indicating that Sanara MedTech is being referred to more favorably in the news media.

Company	Overall Sentiment
QuidelOrtho	Neutral
Sanara MedTech	Positive

QuidelOrtho has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market.

QuidelOrtho presently has a consensus price target of $13.63, indicating a potential downside of 3.37%. Sanara MedTech has a consensus price target of $35.00, indicating a potential downside of 0.40%. Given Sanara MedTech's stronger consensus rating and higher possible upside, analysts clearly believe Sanara MedTech is more favorable than QuidelOrtho.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
QuidelOrtho	2 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Sanara MedTech	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Sanara MedTech has lower revenue, but higher earnings than QuidelOrtho. Sanara MedTech is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
QuidelOrtho	$2.73B	0.35	-$1.13B	-$15.41	N/A
Sanara MedTech	$103.12M	3.13	-$37.56M	-$3.59	N/A

Summary

Sanara MedTech beats QuidelOrtho on 12 of the 15 factors compared between the two stocks.

How does Sanara MedTech compare to Cerus?

Cerus (NASDAQ:CERS) and Sanara MedTech (NASDAQ:SMTI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

In the previous week, Cerus and Cerus both had 1 articles in the media. Cerus' average media sentiment score of 1.02 beat Sanara MedTech's score of 0.60 indicating that Cerus is being referred to more favorably in the media.

Company	Overall Sentiment
Cerus	Positive
Sanara MedTech	Positive

78.4% of Cerus shares are owned by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are owned by institutional investors. 5.3% of Cerus shares are owned by insiders. Comparatively, 42.0% of Sanara MedTech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cerus has higher revenue and earnings than Sanara MedTech. Cerus is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerus	$206.13M	2.21	-$15.63M	-$0.03	N/A
Sanara MedTech	$103.12M	3.13	-$37.56M	-$3.59	N/A

Cerus has a beta of 1.83, meaning that its share price is 83% more volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market.

Cerus presently has a consensus price target of $5.25, indicating a potential upside of 132.30%. Sanara MedTech has a consensus price target of $35.00, indicating a potential downside of 0.40%. Given Cerus' stronger consensus rating and higher probable upside, equities research analysts plainly believe Cerus is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerus	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Sanara MedTech	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Cerus has a net margin of -3.06% compared to Sanara MedTech's net margin of -29.15%. Sanara MedTech's return on equity of 29.72% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cerus	-3.06%	-10.19%	-3.14%
Sanara MedTech	-29.15%	29.72%	2.84%

Summary

Cerus beats Sanara MedTech on 10 of the 15 factors compared between the two stocks.

How does Sanara MedTech compare to Embecta?

Sanara MedTech (NASDAQ:SMTI) and Embecta (NASDAQ:EMBC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

8.1% of Sanara MedTech shares are owned by institutional investors. Comparatively, 93.8% of Embecta shares are owned by institutional investors. 42.0% of Sanara MedTech shares are owned by insiders. Comparatively, 1.3% of Embecta shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Embecta has a net margin of 8.59% compared to Sanara MedTech's net margin of -29.15%. Sanara MedTech's return on equity of 29.72% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-29.15%	29.72%	2.84%
Embecta	8.59%	-19.25%	10.82%

In the previous week, Sanara MedTech and Sanara MedTech both had 1 articles in the media. Embecta's average media sentiment score of 1.82 beat Sanara MedTech's score of 0.60 indicating that Embecta is being referred to more favorably in the news media.

Company	Overall Sentiment
Sanara MedTech	Positive
Embecta	Very Positive

Sanara MedTech has a beta of 1.19, suggesting that its share price is 19% more volatile than the broader market. Comparatively, Embecta has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market.

Sanara MedTech presently has a consensus target price of $35.00, indicating a potential downside of 0.40%. Embecta has a consensus target price of $11.00, indicating a potential upside of 77.42%. Given Embecta's higher probable upside, analysts clearly believe Embecta is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Embecta	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60

Embecta has higher revenue and earnings than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanara MedTech	$103.12M	3.13	-$37.56M	-$3.59	N/A
Embecta	$1.08B	0.33	$95.40M	$1.48	4.19

Summary

Embecta beats Sanara MedTech on 8 of the 14 factors compared between the two stocks.

How does Sanara MedTech compare to OraSure Technologies?

Sanara MedTech (NASDAQ:SMTI) and OraSure Technologies (NASDAQ:OSUR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.

In the previous week, OraSure Technologies had 2 more articles in the media than Sanara MedTech. MarketBeat recorded 3 mentions for OraSure Technologies and 1 mentions for Sanara MedTech. OraSure Technologies' average media sentiment score of 0.75 beat Sanara MedTech's score of 0.60 indicating that OraSure Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Sanara MedTech	Positive
OraSure Technologies	Positive

Sanara MedTech has a net margin of -29.15% compared to OraSure Technologies' net margin of -43.70%. Sanara MedTech's return on equity of 29.72% beat OraSure Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-29.15%	29.72%	2.84%
OraSure Technologies	-43.70%	-19.09%	-16.26%

Sanara MedTech has higher earnings, but lower revenue than OraSure Technologies. Sanara MedTech is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanara MedTech	$103.12M	3.13	-$37.56M	-$3.59	N/A
OraSure Technologies	$115.02M	2.28	-$68.73M	-$0.69	N/A

Sanara MedTech has a beta of 1.19, suggesting that its share price is 19% more volatile than the broader market. Comparatively, OraSure Technologies has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market.

Sanara MedTech currently has a consensus price target of $35.00, indicating a potential downside of 0.40%. OraSure Technologies has a consensus price target of $3.00, indicating a potential downside of 21.26%. Given Sanara MedTech's stronger consensus rating and higher possible upside, equities research analysts plainly believe Sanara MedTech is more favorable than OraSure Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
OraSure Technologies	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

8.1% of Sanara MedTech shares are owned by institutional investors. Comparatively, 93.5% of OraSure Technologies shares are owned by institutional investors. 42.0% of Sanara MedTech shares are owned by insiders. Comparatively, 4.7% of OraSure Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Sanara MedTech beats OraSure Technologies on 9 of the 14 factors compared between the two stocks.

Get Sanara MedTech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SMTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SMTI vs. The Competition

Export

Metric	Sanara MedTech	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$322.96M	$5.58B	$7.27B	$13.21B
Dividend Yield	N/A	1.75%	2.52%	22.89%
P/E Ratio	159.77	20.08	195.99	19.34
Price / Sales	3.13	67.33	562.25	81.55
Price / Cash	59.12	32.25	77.16	53.04
Price / Book	52.45	5.86	10.71	6.03
Net Income	-$37.56M	$146.14M	$3.50B	$380.34M
7 Day Performance	0.26%	-0.97%	-2.90%	-2.32%
1 Month Performance	0.46%	-3.61%	-7.37%	-5.29%
1 Year Performance	17.29%	1.46%	3.05%	-2.94%

Sanara MedTech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SMTI Sanara MedTech	0.7847 of 5 stars	$35.14 0.0%	$35.00 -0.4%	+17.1%	$322.96M	$103.12M	159.77	108
AVNS Avanos Medical	0.0535 of 5 stars	$24.99 flat	N/A	N/A	$1.17B	$715.90M	N/A	4,040
QDEL QuidelOrtho	1.6434 of 5 stars	$12.12 -3.6%	$13.63 +12.4%	-46.4%	$830.66M	$2.73B	N/A	6,500	News Coverage
CERS Cerus	2.3092 of 5 stars	$2.32 -1.1%	$5.25 +126.8%	+44.9%	$466.52M	$206.13M	N/A	345
EMBC Embecta	4.0069 of 5 stars	$6.06 +1.9%	$11.00 +81.4%	-53.6%	$343.08M	$1.02B	4.09	1,850	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SMTI) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sanara MedTech (SMTI) Competitors

SMTI vs. AVNS, QDEL, CERS, EMBC, and OSUR

How does Sanara MedTech compare to Avanos Medical?

Summary

How does Sanara MedTech compare to QuidelOrtho?

Summary

How does Sanara MedTech compare to Cerus?

Summary

How does Sanara MedTech compare to Embecta?

Summary

How does Sanara MedTech compare to OraSure Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMTI vs. The Competition

Sanara MedTech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sanara MedTech (SMTI) Competitors

SMTI vs. AVNS, QDEL, CERS, EMBC, and OSUR

How does Sanara MedTech compare to Avanos Medical?

Do analysts rate AVNS or SMTI?

Which has more volatility & risk, AVNS or SMTI?

Is AVNS or SMTI more profitable?

Does the media favor AVNS or SMTI?

Which has preferable earnings & valuation, AVNS or SMTI?

Do insiders and institutionals believe in AVNS or SMTI?

Summary

How does Sanara MedTech compare to QuidelOrtho?

Is QDEL or SMTI more profitable?

Do insiders & institutionals have more ownership in QDEL or SMTI?

Does the media prefer QDEL or SMTI?

Which has more volatility & risk, QDEL or SMTI?

Do analysts prefer QDEL or SMTI?

Which has stronger earnings and valuation, QDEL or SMTI?

Summary

How does Sanara MedTech compare to Cerus?

Does the media favor CERS or SMTI?

Do institutionals & insiders have more ownership in CERS or SMTI?

Which has preferable earnings & valuation, CERS or SMTI?

Which has more risk & volatility, CERS or SMTI?

Do analysts prefer CERS or SMTI?

Is CERS or SMTI more profitable?

Summary

How does Sanara MedTech compare to Embecta?

Do insiders and institutionals believe in SMTI or EMBC?

Is SMTI or EMBC more profitable?

Does the media refer more to SMTI or EMBC?

Which has more volatility and risk, SMTI or EMBC?

Do analysts recommend SMTI or EMBC?

Which has better earnings and valuation, SMTI or EMBC?

Summary

How does Sanara MedTech compare to OraSure Technologies?

Does the media prefer SMTI or OSUR?

Is SMTI or OSUR more profitable?

Which has preferable earnings and valuation, SMTI or OSUR?

Which has more volatility and risk, SMTI or OSUR?

Do analysts rate SMTI or OSUR?

Do institutionals & insiders believe in SMTI or OSUR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMTI vs. The Competition

Sanara MedTech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools